Lovastatin Tablet
Product Images NDC 43063-939

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 43063-939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063939 Label (43063939)

Lovastatin USP 40 mg tablet package label from PD-Rx Pharmaceuticals, Inc. The label includes dosage strength (40 mg) and tablet count (30 tablets). It features the NDC number 43063-939-30, reorder number, lot number A19E96, and expiration date 05/20. The label also has warnings to keep out of children's reach and to see the package insert for dosage and storage information.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin showing its molecular framework with multiple rings, hydroxyl, and carbonyl groups, corresponding to the active ingredient in Lovastatin tablets.*

FDA Label Image

Table I (Lov00 0004 02)

A data table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing various drugs or grapefruit juice doses alongside corresponding lovastatin doses and AUC ratios. It lists drugs including Gemfibrozil, Itraconazole, Grapefruit Juice (high and low dose), Cyclosporine, and Diltiazem, with details on number of subjects, dosing regimens, and impact on lovastatin exposure.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event on the y-axis against years of follow-up on the x-axis. Two curves are displayed comparing Lovastatin and placebo, with Lovastatin showing a 37% risk reduction (p < 0.001) over approximately 6 years.*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing various interacting agents such as CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, and others. It provides prescribing recommendations for each, including contraindications and dosage limits when used with lovastatin, along with advice to avoid grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.